Search clinical trials for: Rubella vaccine safety

Total 50547 results

Novartis Vaccines

Completed

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Influenza

Finland, United States, Poland
Pfizer

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Group B Streptococcus Infections

United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
PharmaJet, Inc.
United States Department of Defense

Active, not recruiting

Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection

Vaccine Reaction

United States
Dynavax Technologies Corporation
United States Department of Defense

Completed

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Cervical Intraepithelial Neoplasia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Vaxart

Completed

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (VXA-NVV-105)

Norovirus Infections

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)

Respiratory Syncytial Virus Infections

Spain, Japan, Italy, United States, Australia, Canada, Korea, Republic of, Germany
Pfizer

Active, not recruiting

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Lyme Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

Argentina, United States, Germany, Spain, Poland, Canada, Japan, Netherlands
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Schistosomiasis

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Dengue Virus | Dengue Disease

United States, Australia, Canada, Finland, Germany, Israel, Taiwan
Hipra Scientific, S.L.U

Active, not recruiting

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

SARS-CoV2 Infection

Spain
BioNTech SE

Active, not recruiting

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
VBI Vaccines Inc.

Completed

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Covid19

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
AstraZeneca

Active, not recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)

Non-muscle-invasive Bladder Cancer

France, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
Seqirus
Biomedical Advanced Research and Development Authority

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

Respiratory Syncytial Virus Infection

United States, Puerto Rico
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (COVID-19)

COVID-19 | Influenza

Australia, New Zealand
National Institute of Allergy and Infectious Diseases...

Terminated

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

H3N2 Influenza

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (RSVictory)

Respiratory Syncytial Virus

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
AstraZeneca

Active, not recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
IrsiCaixa
Hospital Clinic of Barcelona; University of Oxford; Germans Trias i Pujol Hospital and other collaborators

Completed

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

HIV

Spain
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Pneumonia, Pneumococcal

United States, Canada, France, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan
IrsiCaixa
José Moltó Marhuenda, PhD, MD; Beatriz Mothe Pujadas PhD,MD; Susana Benet Garrabé... and other collaborators

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

HIV Infection

Spain
IrsiCaixa
Hospital Clinic of Barcelona; University of Oxford; Fundación FLS de Lucha Contra... and other collaborators

Completed

Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

HIV

Spain
Celgene

Active, not recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
Butantan Institute
Valneva Austria GmbH

Completed

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Chikungunya

Brazil
Henry M. Jackson Foundation for the Advancement...
US Military HIV Research Program; Janssen Vaccines & Prevention B.V.

Withdrawn

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (RV582)

HIV-1-infection

Thailand
Henry M. Jackson Foundation for the Advancement...
Johns Hopkins University; Karolinska Institutet; University of Miami; Chulalongkorn... and other collaborators

Active, not recruiting

Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth (HVRRICANE)

HIV Infections

South Africa
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Completed

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
International AIDS Vaccine Initiative
Emory University; Fred Hutchinson Cancer Center; George Washington University; ModernaTX... and other collaborators

Active, not recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Hiv

United States
Pfizer

Completed

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age (PICASSO)

RESPIRATORY SYNCYTIAL VIRUS (RSV)

United States
CureVac

Completed

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Covid19 | SARS-CoV-2

Belgium, Spain, Germany, Argentina, Colombia, Dominican Republic, Mexico, Netherlands, Panama, Peru
Scynexis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Coccidioidomycosis | Invasive Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Histoplasmosis | Chronic Pulmonary Aspergillosis | Blastomycosis | Invasive Candidiasis | Recurrent Vulvovaginal Candidiasis | Mucocutaneous Candidiasis | Other Emerging Fungi

United States, Spain, United Kingdom, Austria, Pakistan, South Africa, Germany, Netherlands
Centre Hospitalier Universitaire de Saint Etienne

Active, not recruiting

Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen (CoviCompare_J)

Healthy Volunteers

France
National Institute of Allergy and Infectious Diseases...
Moderna TX, Inc

Active, not recruiting

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Nipah Virus Infection

United States
Pfizer

Completed

A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

Pneumococcal Disease

India
WestVac Biopharma Co., Ltd.
West China Hospital

Completed

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

China
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) (PNEU-PED-KOR)

Pneumococcal Disease

Korea, Republic of
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Cytomegalovirus Infection

United States, Australia, Canada, France, Belgium, Germany, Israel, Italy, United Kingdom, Spain, Estonia, Finland, Japan
WestVac Biopharma Co., Ltd.
West China Hospital

Active, not recruiting

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

COVID-19

Philippines, Indonesia, Kenya, Mexico, Nepal
WestVac Biopharma Co., Ltd.

Completed

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Philippines

3

Subscribe